Polar Capital's Pinniger: Which biotech companies are the big pharmas of the future?

Best-performing fund over five years

Polar Capital's David Pinniger has said there will be a "second stage" of biotech companies coming onto the market, providing the sector with the potential for further robust returns as it approaches the halfway point of a decade-long cycle.

Pinniger, who runs the $427m Polar Capital Biotechnology fund, said people questioned whether biotech had further to run when the fund was launched on 31 October 2013 as the NASDAQ Biotechnology index had already returned 131% over the previous three years. Since launch five years ago to 13 August, it has returned 219%  versus returns of 118% by the NASDAQ Biotechnology index, according to FE. This strong performance means it has been the best-performing fund in the entire Investment Association universe over its tenure.  BB Biotech: Spotting tomorrow's winners today The manager sa...